Home / Going-concern warnings / Sigyn Therapeutics, Inc.
Filed 2025-09-05 路 Form 10-Q 路 Accession 0001641172-25-026704 nano
Price before filing: $4.6 (2025-09-04 close, split/dividend-adjusted)
Market cap at flag: $7.4M (2025-09-05) 路 Latest: $65,713 (2026-10-16)
| Window | SIGY | SPY | vs SPY | |
|---|---|---|---|---|
| 30 days | -40.0% | +3.8% | -43.8% | 2025-10-06 |
| 90 days | -56.5% | +5.7% | -62.2% | 2025-12-04 |
| 180 days | -99.0% | +6.2% | -105.2% | 2026-03-04 |
Return from the last close before the filing date to the first close on/after the window end. Pending windows have not fully elapsed. Past performance says nothing certain about the future.
"These matters raise substantial doubt about the Company's ability to continue as a going concern."
Quoted from the filing. Source
The filing states that substantial doubt exists about the company's ability to continue as a going concern: it may not have enough cash to last the next 12 months. Expect dilution, debt deals or worse. An auditor's going-concern paragraph is the strongest form of this warning.
Source: management disclosure in Form 10-Q (period 2025-06-30)
Why this score: quarterly (unaudited) disclosure; also within 90 days: Late quarterly report (NT 10-Q)
Read the original filing on SEC.gov →
Not investment advice. Automated summary; verify against the filing.
The week's most serious auditor changes, restatements, late filings and going-concern warnings, in plain English. Free. Unsubscribe anytime.
Newsletter delivered by beehiiv. See our privacy policy.